Grifols is a global healthcare company founded in Barcelona in 1909 that develops and produces plasma-derived medicines, biopharmaceutical solutions, clinical diagnostic technologies, and biological supplies for life-science research and pharmaceutical manufacturing. The company operates the world's largest network of plasma donation centers and serves patients across more than 110 countries, with employee presence in over 30 countries and regions spanning North America, Europe, Africa, the Middle East, and China.
The company's therapeutic focus spans immunology, infectious diseases, pulmonology, critical care, hepatology, hematology, and neurology, with products designed to address chronic, rare, and life-threatening conditions. Grifols maintains an integrated portfolio that extends from plasma collection through transfusion medicine, offering safety solutions that span the entire donation-to-transfusion process alongside clinical diagnostic technologies.
With over 23,000 employees, Grifols operates at scale across multiple business lines, combining traditional pharmaceutical manufacturing with advanced biopharmaceutical research and development. The company's infrastructure includes both manufacturing facilities and a distributed network of clinical and research operations that support its position as a recognized leader in transfusion medicine and plasma therapeutics.
